Plasma level of soluble urokinase‐type plasminogen activator receptor as a predictor of disease severity and case fatality in patients with bacteraemia: a prospective cohort study
Huttunen R, Syrjänen J, Vuento R, Hurme M, Huhtala H, Laine J, Pessi T, Aittoniemi J (Tampere University Hospital; University of Tampere Medical School, University of Tampere; Centre for Laboratory Medicine, Pirkanmaa Hospital District; University of Tampere Medical School; School of Health Sciences...
Saved in:
| Published in | Journal of internal medicine Vol. 270; no. 1; pp. 32 - 40 |
|---|---|
| Main Authors | , , , , , , , |
| Format | Journal Article |
| Language | English |
| Published |
Oxford, UK
Blackwell Publishing Ltd
01.07.2011
Blackwell |
| Subjects | |
| Online Access | Get full text |
Cover
Loading…
| Abstract | Huttunen R, Syrjänen J, Vuento R, Hurme M, Huhtala H, Laine J, Pessi T, Aittoniemi J (Tampere University Hospital; University of Tampere Medical School, University of Tampere; Centre for Laboratory Medicine, Pirkanmaa Hospital District; University of Tampere Medical School; School of Health Sciences, University of Tampere; and Medical School, University of Tampere; Tampere, Finland) Plasma level of soluble urokinase‐type plasminogen activator receptor as a predictor of disease severity and case fatality in patients with bacteraemia: a prospective cohort study. J Intern Med 2011; 270: 32–40.
. Objectives. Urokinase‐type plasminogen activator receptor (uPAR) is expressed on a variety of different immune cells and vascular endothelial cells during inflammation. Previous studies indicate that a high plasma concentration of the soluble form of the receptor (suPAR) predicts poor outcome in infectious diseases.
Design. A prospective cohort study.
Subjects and methods. Plasma suPAR levels were measured in 132 patients with bacteraemia caused by Staphylococcus aureus, Streptococcus pneumoniae, ß‐haemolytic streptococcae or Escherichia coli using a commercial enzyme‐linked immunosorbent assay (ELISA). Values were measured on days 1–4 after a positive blood culture, on days 13–18 and on recovery.
Results. The maximum suPAR values on days 1–4 were markedly higher in nonsurvivors compared to survivors (15.8 vs. 7.3 ng mL−1, P < 0.001) and the area under the receiver operating characteristic curve (AUCROC) in the prediction of case fatality was 0.84 (95% confidence interval (CI) 0.76–0.93, P < 0.001). At a cut‐off level of 11.0 ng mL−1, the sensitivity and specificity of suPAR for fatal disease was 83% and 76%, respectively. A high level of suPAR (≥11 ng mL−1) was associated with hypotension (mean arterial pressure <70 mmHg) (odds ratio (OR) 6.5; 95% CI 2.9–14.6) and high sequential organ failure assessment score (≥4) (OR 9.3; 95% CI 4.0–21.9). A high suPAR level remained an independent risk factor for case fatality in a logistic regression model adjusted for potential confounders.
Conclusion. Plasma suPAR level is a sensitive and specific independent prognostic biomarker in patients with bacteraemia. |
|---|---|
| AbstractList | Urokinase-type plasminogen activator receptor (uPAR) is expressed on a variety of different immune cells and vascular endothelial cells during inflammation. Previous studies indicate that a high plasma concentration of the soluble form of the receptor (suPAR) predicts poor outcome in infectious diseases.
A prospective cohort study.
Plasma suPAR levels were measured in 132 patients with bacteraemia caused by Staphylococcus aureus, Streptococcus pneumoniae, ß-haemolytic streptococcae or Escherichia coli using a commercial enzyme-linked immunosorbent assay (ELISA). Values were measured on days 1-4 after a positive blood culture, on days 13-18 and on recovery.
The maximum suPAR values on days 1-4 were markedly higher in nonsurvivors compared to survivors (15.8 vs. 7.3 ng mL(-1) , P < 0.001) and the area under the receiver operating characteristic curve (AUC(ROC) ) in the prediction of case fatality was 0.84 (95% confidence interval (CI) 0.76-0.93, P < 0.001). At a cut-off level of 11.0 ng mL(-1) , the sensitivity and specificity of suPAR for fatal disease was 83% and 76%, respectively. A high level of suPAR (≥ 11 ng mL(-1) ) was associated with hypotension (mean arterial pressure < 70 mmHg) (odds ratio (OR) 6.5; 95% CI 2.9-14.6) and high sequential organ failure assessment score (≥ 4) (OR 9.3; 95% CI 4.0-21.9). A high suPAR level remained an independent risk factor for case fatality in a logistic regression model adjusted for potential confounders.
Plasma suPAR level is a sensitive and specific independent prognostic biomarker in patients with bacteraemia. Huttunen R, Syrjänen J, Vuento R, Hurme M, Huhtala H, Laine J, Pessi T, Aittoniemi J (Tampere University Hospital; University of Tampere Medical School, University of Tampere; Centre for Laboratory Medicine, Pirkanmaa Hospital District; University of Tampere Medical School; School of Health Sciences, University of Tampere; and Medical School, University of Tampere; Tampere, Finland) Plasma level of soluble urokinase‐type plasminogen activator receptor as a predictor of disease severity and case fatality in patients with bacteraemia: a prospective cohort study. J Intern Med 2011; 270: 32–40. . Objectives. Urokinase‐type plasminogen activator receptor (uPAR) is expressed on a variety of different immune cells and vascular endothelial cells during inflammation. Previous studies indicate that a high plasma concentration of the soluble form of the receptor (suPAR) predicts poor outcome in infectious diseases. Design. A prospective cohort study. Subjects and methods. Plasma suPAR levels were measured in 132 patients with bacteraemia caused by Staphylococcus aureus, Streptococcus pneumoniae, ß‐haemolytic streptococcae or Escherichia coli using a commercial enzyme‐linked immunosorbent assay (ELISA). Values were measured on days 1–4 after a positive blood culture, on days 13–18 and on recovery. Results. The maximum suPAR values on days 1–4 were markedly higher in nonsurvivors compared to survivors (15.8 vs. 7.3 ng mL−1, P < 0.001) and the area under the receiver operating characteristic curve (AUCROC) in the prediction of case fatality was 0.84 (95% confidence interval (CI) 0.76–0.93, P < 0.001). At a cut‐off level of 11.0 ng mL−1, the sensitivity and specificity of suPAR for fatal disease was 83% and 76%, respectively. A high level of suPAR (≥11 ng mL−1) was associated with hypotension (mean arterial pressure <70 mmHg) (odds ratio (OR) 6.5; 95% CI 2.9–14.6) and high sequential organ failure assessment score (≥4) (OR 9.3; 95% CI 4.0–21.9). A high suPAR level remained an independent risk factor for case fatality in a logistic regression model adjusted for potential confounders. Conclusion. Plasma suPAR level is a sensitive and specific independent prognostic biomarker in patients with bacteraemia. Objectives. Urokinase-type plasminogen activator receptor (uPAR) is expressed on a variety of different immune cells and vascular endothelial cells during inflammation. Previous studies indicate that a high plasma concentration of the soluble form of the receptor (suPAR) predicts poor outcome in infectious diseases. Design. A prospective cohort study. Subjects and methods. Plasma suPAR levels were measured in 132 patients with bacteraemia caused by Staphylococcus aureus, Streptococcus pneumoniae, s-haemolytic streptococcae or Escherichia coli using a commercial enzyme-linked immunosorbent assay (ELISA). Values were measured on days 1-4 after a positive blood culture, on days 13-18 and on recovery. Results. The maximum suPAR values on days 1-4 were markedly higher in nonsurvivors compared to survivors (15.8 vs. 7.3ngmL-1, P<0.001) and the area under the receiver operating characteristic curve (AUCROC) in the prediction of case fatality was 0.84 (95% confidence interval (CI) 0.76-0.93, P<0.001). At a cut-off level of 11.0ngmL-1, the sensitivity and specificity of suPAR for fatal disease was 83% and 76%, respectively. A high level of suPAR ( greater than or equal to 11ng mL-1) was associated with hypotension (mean arterial pressure <70mmHg) (odds ratio (OR) 6.5; 95% CI 2.9-14.6) and high sequential organ failure assessment score ( greater than or equal to 4) (OR 9.3; 95% CI 4.0-21.9). A high suPAR level remained an independent risk factor for case fatality in a logistic regression model adjusted for potential confounders. Conclusion. Plasma suPAR level is a sensitive and specific independent prognostic biomarker in patients with bacteraemia.Original Abstract: Abstract. Huttunen R, Syrjaenen J, Vuento R, Hurme M, Huhtala H, Laine J, Pessi T, Aittoniemi J (Tampere University Hospital; University of Tampere Medical School, University of Tampere; Centre for Laboratory Medicine, Pirkanmaa Hospital District; University of Tampere Medical School; School of Health Sciences, University of Tampere; and Medical School, University of Tampere; Tampere, Finland) Plasma level of soluble urokinase-type plasminogen activator receptor as a predictor of disease severity and case fatality in patients with bacteraemia: a prospective cohort study. J Intern Med 2011; 270: 32-40. Urokinase-type plasminogen activator receptor (uPAR) is expressed on a variety of different immune cells and vascular endothelial cells during inflammation. Previous studies indicate that a high plasma concentration of the soluble form of the receptor (suPAR) predicts poor outcome in infectious diseases.OBJECTIVESUrokinase-type plasminogen activator receptor (uPAR) is expressed on a variety of different immune cells and vascular endothelial cells during inflammation. Previous studies indicate that a high plasma concentration of the soluble form of the receptor (suPAR) predicts poor outcome in infectious diseases.A prospective cohort study.DESIGNA prospective cohort study.Plasma suPAR levels were measured in 132 patients with bacteraemia caused by Staphylococcus aureus, Streptococcus pneumoniae, ß-haemolytic streptococcae or Escherichia coli using a commercial enzyme-linked immunosorbent assay (ELISA). Values were measured on days 1-4 after a positive blood culture, on days 13-18 and on recovery.SUBJECTS AND METHODSPlasma suPAR levels were measured in 132 patients with bacteraemia caused by Staphylococcus aureus, Streptococcus pneumoniae, ß-haemolytic streptococcae or Escherichia coli using a commercial enzyme-linked immunosorbent assay (ELISA). Values were measured on days 1-4 after a positive blood culture, on days 13-18 and on recovery.The maximum suPAR values on days 1-4 were markedly higher in nonsurvivors compared to survivors (15.8 vs. 7.3 ng mL(-1) , P < 0.001) and the area under the receiver operating characteristic curve (AUC(ROC) ) in the prediction of case fatality was 0.84 (95% confidence interval (CI) 0.76-0.93, P < 0.001). At a cut-off level of 11.0 ng mL(-1) , the sensitivity and specificity of suPAR for fatal disease was 83% and 76%, respectively. A high level of suPAR (≥ 11 ng mL(-1) ) was associated with hypotension (mean arterial pressure < 70 mmHg) (odds ratio (OR) 6.5; 95% CI 2.9-14.6) and high sequential organ failure assessment score (≥ 4) (OR 9.3; 95% CI 4.0-21.9). A high suPAR level remained an independent risk factor for case fatality in a logistic regression model adjusted for potential confounders.RESULTSThe maximum suPAR values on days 1-4 were markedly higher in nonsurvivors compared to survivors (15.8 vs. 7.3 ng mL(-1) , P < 0.001) and the area under the receiver operating characteristic curve (AUC(ROC) ) in the prediction of case fatality was 0.84 (95% confidence interval (CI) 0.76-0.93, P < 0.001). At a cut-off level of 11.0 ng mL(-1) , the sensitivity and specificity of suPAR for fatal disease was 83% and 76%, respectively. A high level of suPAR (≥ 11 ng mL(-1) ) was associated with hypotension (mean arterial pressure < 70 mmHg) (odds ratio (OR) 6.5; 95% CI 2.9-14.6) and high sequential organ failure assessment score (≥ 4) (OR 9.3; 95% CI 4.0-21.9). A high suPAR level remained an independent risk factor for case fatality in a logistic regression model adjusted for potential confounders.Plasma suPAR level is a sensitive and specific independent prognostic biomarker in patients with bacteraemia.CONCLUSIONPlasma suPAR level is a sensitive and specific independent prognostic biomarker in patients with bacteraemia. |
| Author | Hurme, M. Huttunen, R. Syrjänen, J. Laine, J. Vuento, R. Huhtala, H. Pessi, T. Aittoniemi, J. |
| Author_xml | – sequence: 1 givenname: R. surname: Huttunen fullname: Huttunen, R. – sequence: 2 givenname: J. surname: Syrjänen fullname: Syrjänen, J. – sequence: 3 givenname: R. surname: Vuento fullname: Vuento, R. – sequence: 4 givenname: M. surname: Hurme fullname: Hurme, M. – sequence: 5 givenname: H. surname: Huhtala fullname: Huhtala, H. – sequence: 6 givenname: J. surname: Laine fullname: Laine, J. – sequence: 7 givenname: T. surname: Pessi fullname: Pessi, T. – sequence: 8 givenname: J. surname: Aittoniemi fullname: Aittoniemi, J. |
| BackLink | http://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=24243120$$DView record in Pascal Francis https://www.ncbi.nlm.nih.gov/pubmed/21332843$$D View this record in MEDLINE/PubMed |
| BookMark | eNqFkstu1TAQhi1URE8PvALyBrFK8CU3s0BCFZeiorKAtTWxJ9QHnyTETtvseARehhfiSYjbQ1nizYxnPv8zkv8TctQPPRJCOcv5el7sci6rMhO1qnLBOM-ZkJXMbx6QzX3jiGyYKousagQ7Jich7BjjklXsETkWXErRFHJDfn3yEPZAPV6hp0NHw-Dn1iOdp-Gb6yHg7x8_4zIiHRPo-uEr9hRMdFcQh4lOaHBMCQQKdJzQOpOuq5J1Adf3NKzSk4sLhd5SkyodRPCp4no6QnTYx0CvXbyk7aqME-DewctbvSGMmIYhNcPlMEUa4myXx-RhBz7gk0Pcki9v33w-fZ-dX7w7O319no2yrmUmoWWGAyrW2dZiXckasbZcMSUV8LKSvIGy6tDyVpnGMGssK1QhKyx4wVFuyfM73XWR7zOGqPcuGPQeehzmoBuleClFLf5P1qKQtVxHbsnTAzm3e7R6nNwepkX__ZMVeHYAIBjw3QS9ceEfV6xKXLCVe3XHXTuPy32fM508onc6WUEnK-jkEX3rEX2jP1ycfUyp_ANf8Law |
| ContentType | Journal Article |
| Copyright | 2011 The Association for the Publication of the Journal of Internal Medicine 2015 INIST-CNRS 2011 The Association for the Publication of the Journal of Internal Medicine. |
| Copyright_xml | – notice: 2011 The Association for the Publication of the Journal of Internal Medicine – notice: 2015 INIST-CNRS – notice: 2011 The Association for the Publication of the Journal of Internal Medicine. |
| DBID | IQODW CGR CUY CVF ECM EIF NPM 7X8 7QL C1K |
| DOI | 10.1111/j.1365-2796.2011.02363.x |
| DatabaseName | Pascal-Francis Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed MEDLINE - Academic Bacteriology Abstracts (Microbiology B) Environmental Sciences and Pollution Management |
| DatabaseTitle | MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) MEDLINE - Academic Bacteriology Abstracts (Microbiology B) Environmental Sciences and Pollution Management |
| DatabaseTitleList | MEDLINE Bacteriology Abstracts (Microbiology B) MEDLINE - Academic |
| Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Medicine |
| EISSN | 1365-2796 |
| EndPage | 40 |
| ExternalDocumentID | 21332843 24243120 JOIM2363 |
| Genre | article Research Support, Non-U.S. Gov't Journal Article |
| GroupedDBID | --- .3N .55 .GA .GJ .Y3 05W 0R~ 10A 1OB 1OC 29K 2WC 31~ 33P 36B 3O- 3SF 4.4 50Y 50Z 51W 51X 52M 52N 52O 52P 52R 52S 52T 52U 52V 52W 52X 53G 5GY 5HH 5LA 5RE 5VS 66C 702 7PT 8-0 8-1 8-3 8-4 8-5 8UM 930 A01 A03 AAESR AAEVG AAHQN AAIPD AAMMB AAMNL AANHP AANLZ AAONW AASGY AAWTL AAXRX AAYCA AAZKR ABCQN ABCUV ABEML ABJNI ABLJU ABOCM ABPVW ABQWH ABXGK ACAHQ ACBWZ ACCZN ACGFO ACGFS ACGOF ACMXC ACPOU ACPRK ACRPL ACSCC ACXBN ACXQS ACYXJ ADBBV ADBTR ADEOM ADIZJ ADKYN ADMGS ADNMO ADOZA ADXAS ADZMN AEFGJ AEGXH AEIGN AEIMD AENEX AEUYR AEYWJ AFBPY AFEBI AFFNX AFFPM AFGKR AFRAH AFWVQ AFZJQ AGHNM AGQPQ AGXDD AGYGG AHBTC AHEFC AI. AIACR AIAGR AIDQK AIDYY AITYG AIURR ALAGY ALMA_UNASSIGNED_HOLDINGS ALUQN ALVPJ AMBMR AMYDB ATUGU AZBYB AZFZN AZVAB BAFTC BAWUL BDRZF BFHJK BHBCM BMXJE BROTX BRXPI BY8 C45 CAG COF CS3 D-6 D-7 D-E D-F D-I DCZOG DIK DPXWK DR2 DRFUL DRMAN DRSTM DU5 DUUFO E3Z EBS EJD EMOBN EX3 F00 F01 F04 F5P FEDTE FIJ FUBAC G-S G.N GODZA H.X HF~ HGLYW HVGLF HZI HZ~ IHE IX1 J0M KBYEO LATKE LC2 LC3 LEEKS LH4 LITHE LOXES LP6 LP7 LUTES LW6 LYRES MEWTI MK4 MRFUL MRMAN MRSTM MSFUL MSMAN MSSTM MXFUL MXMAN MXSTM N04 N05 N4W N9A NF~ O66 O9- OIG OK1 OVD P2P P2W P2X P2Z P4B P4D PALCI PQQKQ Q.N Q11 QB0 R.K RIWAO RJQFR ROL RX1 SAMSI SJN SUPJJ TEORI TR2 UB1 V8K V9Y VH1 VVN W8V W99 WBKPD WH7 WHWMO WIH WIJ WIK WIN WOHZO WOW WQJ WVDHM WXI WXSBR X7M XG1 YFH YOC YUY ZCG ZGI ZXP ZZTAW ~IA ~WT IQODW CGR CUY CVF ECM EIF NPM 7X8 7QL C1K |
| ID | FETCH-LOGICAL-p3773-3ab0c1ae90fdbde7637ee7d190939a156318a56fed1b9c8c0dcd049436e4141e3 |
| IEDL.DBID | DR2 |
| ISSN | 0954-6820 1365-2796 |
| IngestDate | Thu Jul 10 23:27:19 EDT 2025 Fri Jul 11 04:28:03 EDT 2025 Mon Jul 21 05:33:13 EDT 2025 Mon Jul 21 09:14:14 EDT 2025 Wed Aug 20 07:25:34 EDT 2025 |
| IsDoiOpenAccess | false |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 1 |
| Keywords | u-Plasminogen activator Biological marker Soluble form Blood plasma Prospective Sepsis syndrome suPAR Cohort study Evolution Public health outcome Biological receptor Human Serine endopeptidases Enzyme Mortality bacteraemia Biological indicator Patient biomarker Bacteremia Infection Peptidases Bacteriosis Phenotype variation soluble urokinase-type plasminogen activator receptor Hydrolases Death Predictive factor sepsis |
| Language | English |
| License | CC BY 4.0 2011 The Association for the Publication of the Journal of Internal Medicine. |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-p3773-3ab0c1ae90fdbde7637ee7d190939a156318a56fed1b9c8c0dcd049436e4141e3 |
| Notes | This work was carried out in Tampere University Hospital and the University of Tampere Medical School, Tampere, Finland. Click here to view the Editorial Comment by J. Eugen‐Olsen ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 ObjectType-Article-2 ObjectType-Feature-1 |
| OpenAccessLink | https://onlinelibrary.wiley.com/doi/pdfdirect/10.1111/j.1365-2796.2011.02363.x |
| PMID | 21332843 |
| PQID | 872437356 |
| PQPubID | 23479 |
| PageCount | 9 |
| ParticipantIDs | proquest_miscellaneous_899153272 proquest_miscellaneous_872437356 pubmed_primary_21332843 pascalfrancis_primary_24243120 wiley_primary_10_1111_j_1365_2796_2011_02363_x_JOIM2363 |
| PublicationCentury | 2000 |
| PublicationDate | July 2011 |
| PublicationDateYYYYMMDD | 2011-07-01 |
| PublicationDate_xml | – month: 07 year: 2011 text: July 2011 |
| PublicationDecade | 2010 |
| PublicationPlace | Oxford, UK |
| PublicationPlace_xml | – name: Oxford, UK – name: Oxford – name: England |
| PublicationTitle | Journal of internal medicine |
| PublicationTitleAlternate | J Intern Med |
| PublicationYear | 2011 |
| Publisher | Blackwell Publishing Ltd Blackwell |
| Publisher_xml | – name: Blackwell Publishing Ltd – name: Blackwell |
| References | 2001; 276 2004; 10 2010; 33 1997; 227 2003; 348 2009; 31 2000; 12 1962; 110 2002; 168 2004; 36 2010; 268 2002; 6 2000; 96 2007; 7 2008; 68 2000; 165 2010; 184 1999; 107 2007; 11 2009; 27 2009; 37 2001; 345 1996; 22 21366732 - J Intern Med. 2011 Jul;270(1):29-31 |
| References_xml | – volume: 165 start-page: 1513 year: 2000 end-page: 9 article-title: Urokinase receptor‐deficient mice have impaired neutrophil recruitment in response to pulmonary Pseudomonas aeruginosa infection publication-title: J Immunol – volume: 107 start-page: 160 year: 1999 end-page: 7 article-title: The urokinase plasminogen activator receptor in blood from healthy individuals and patients with cancer publication-title: APMIS – volume: 11 start-page: R38 year: 2007 article-title: Use of plasma C‐reactive protein, procalcitonin, neutrophils, macrophage migration inhibitory factor, soluble urokinase‐type plasminogen activator receptor, and soluble triggering receptor expressed on myeloid cells‐1 in combination to diagnose infections: a prospective study publication-title: Crit Care – volume: 227 start-page: 46 year: 1997 end-page: 63 article-title: Mathematical tools for demonstrating the clinical usefulness of biochemical markers publication-title: Scand J Clin Lab Invest Suppl – volume: 345 start-page: 1368 year: 2001 end-page: 77 article-title: Early goal‐directed therapy in the treatment of severe sepsis and septic shock publication-title: N Engl J Med – volume: 33 start-page: 149 year: 2010 end-page: 54 article-title: High activity of indoleamine 2,3 dioxygenase enzyme predicts disease severity and case fatality in bacteremic patients publication-title: Shock – volume: 12 start-page: 613 year: 2000 end-page: 20 article-title: Urokinase receptor and integrin partnership: coordination of signaling for cell adhesion, migration and growth publication-title: Curr Opin Cell Biol – volume: 348 start-page: 138 year: 2003 end-page: 50 article-title: The pathophysiology and treatment of sepsis publication-title: N Engl J Med – volume: 31 start-page: 448 year: 2009 end-page: 53 article-title: Endothelial nitric oxide synthase G894T (Glu298Asp) polymorphism is associated with hypotension in patients with bacteremia but not in bacteremia caused by a gram‐positive organism publication-title: Shock – volume: 276 start-page: 3983 year: 2001 end-page: 90 article-title: Urokinase‐type plasminogen activator receptor (CD87) is a ligand for integrins and mediates cell‐cell interaction publication-title: J Biol Chem – volume: 7 start-page: 41 year: 2007 article-title: Plasma levels of soluble urokinase‐type plasminogen activator receptor (suPAR) and early mortality risk among patients enrolling for antiretroviral treatment in South Africa publication-title: BMC Infect Dis – volume: 10 start-page: 409 year: 2004 end-page: 15 article-title: The plasma level of soluble urokinase receptor is elevated in patients with bacteraemia and predicts mortality publication-title: Clin Microbiol Infect – volume: 96 start-page: 4091 year: 2000 end-page: 5 article-title: Serum level of soluble urokinase‐type plasminogen activator receptor is a strong and independent predictor of survival in human immunodeficiency virus infection publication-title: Blood – volume: 37 start-page: 2290 year: 2009 end-page: 8 article-title: Biomarkers of sepsis publication-title: Crit Care Med – volume: 184 start-page: 3079 year: 2010 end-page: 86 article-title: Urokinase receptor is necessary for bacterial defense against pneumonia‐derived septic melioidosis by facilitating phagocytosis publication-title: J Immunol – volume: 27 start-page: 157 year: 2009 end-page: 72 article-title: suPAR: the molecular crystal ball publication-title: Dis Markers – volume: 268 start-page: 296 year: 2010 end-page: 308 article-title: Circulating soluble urokinase plasminogen activator receptor predicts cancer, cardiovascular disease, diabetes and mortality in the general population publication-title: J Intern Med – volume: 22 start-page: 707 year: 1996 end-page: 10 article-title: The SOFA (Sepsis‐related Organ Failure Assessment) score to describe organ dysfunction/failure. On behalf of the Working Group on Sepsis‐Related Problems of the European Society of Intensive Care Medicine publication-title: Intensive Care Med – volume: 68 start-page: 438 year: 2008 end-page: 44 article-title: Gene‐environment interaction between MBL2 genotype and smoking, and the risk of gram‐positive bacteraemia publication-title: Scand J Immunol – volume: 7 start-page: 13 year: 2007 article-title: Obesity and smoking are factors associated with poor prognosis in patients with bacteraemia publication-title: BMC Infect Dis – volume: 168 start-page: 3507 year: 2002 end-page: 11 article-title: Urokinase receptor is necessary for adequate host defense against pneumococcal pneumonia publication-title: J Immunol – volume: 36 start-page: 14 year: 2004 end-page: 9 article-title: Soluble urokinase receptor is elevated in cerebrospinal fluid from patients with purulent meningitis and is associated with fatal outcome publication-title: Scand J Infect Dis – volume: 110 start-page: 856 year: 1962 end-page: 64 article-title: Gram‐negative bacteremia. II. Clinical, laboratory, and therapeutic observations publication-title: Arch Intern Med – volume: 6 start-page: 686 year: 2002 end-page: 92 article-title: The serum level of soluble urokinase receptor is elevated in tuberculosis patients and predicts mortality during treatment: a community study from Guinea‐Bissau publication-title: Int J Tuberc Lung Dis – reference: 21366732 - J Intern Med. 2011 Jul;270(1):29-31 |
| SSID | ssj0013060 |
| Score | 2.3823538 |
| Snippet | Huttunen R, Syrjänen J, Vuento R, Hurme M, Huhtala H, Laine J, Pessi T, Aittoniemi J (Tampere University Hospital; University of Tampere Medical School,... Urokinase-type plasminogen activator receptor (uPAR) is expressed on a variety of different immune cells and vascular endothelial cells during inflammation.... Objectives. Urokinase-type plasminogen activator receptor (uPAR) is expressed on a variety of different immune cells and vascular endothelial cells during... |
| SourceID | proquest pubmed pascalfrancis wiley |
| SourceType | Aggregation Database Index Database Publisher |
| StartPage | 32 |
| SubjectTerms | Adolescent Adult Aged Aged, 80 and over bacteraemia Bacteremia Bacteremia - diagnosis Bacterial diseases Bacterial sepsis Biological and medical sciences biomarker biomarkers Biomarkers - blood Blood culture Blood pressure Endothelial cells Enzyme-linked immunosorbent assay Epidemiologic Methods Escherichia coli Female General aspects Human bacterial diseases Humans Hypotension Infectious diseases Inflammation Male Medical sciences Middle Aged Miscellaneous outcome Plasma levels Prognosis Public health. Hygiene Public health. Hygiene-occupational medicine Receptors, Urokinase Plasminogen Activator - blood Regression analysis Risk factors sepsis soluble urokinase‐type plasminogen activator receptor Staphylococcus aureus Streptococcus pneumoniae suPAR u-Plasminogen activator Young Adult |
| Title | Plasma level of soluble urokinase‐type plasminogen activator receptor as a predictor of disease severity and case fatality in patients with bacteraemia: a prospective cohort study |
| URI | https://onlinelibrary.wiley.com/doi/abs/10.1111%2Fj.1365-2796.2011.02363.x https://www.ncbi.nlm.nih.gov/pubmed/21332843 https://www.proquest.com/docview/872437356 https://www.proquest.com/docview/899153272 |
| Volume | 270 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV3NatwwEBYlh9BL_3-2bcIcevViW5Jl51ZCQhrYtpQGchOSLMGyiW3Wu6H0lEfoy_SF-iSdkb1Jt6SX0pvXPwP2fjP6NJr5xNhbVVYiD_gPlFLKROQ2T0zlXeKVFEGkxpZRZ3b2oTg5E6fn8nysf6JemEEf4ibhRp4R4zU5uLH9tpMP_VRVMSpx5rzgU-KTdIH40ef8dkEhjQ3DSChEUuCot13Uc6chKpM0PX6pMGxxcRcH3aa0cUw6fsgWm7cZSlEW0_XKTt23P4Qe_8_rPmIPRuoK7wasPWb3fPOE7c7Gxfmn7McnZOKXBi6oDgnaAARre-FhvWwX8waHy5_X3ynlCx3dOG9aBC9QY8UVzfwBY6_v6MD0YKBbkmH6iZbGZSTAYdzTbntgmhocnQmUfqIz8wZGjdgeKLkMNupQG385NwfRXrvpKgXaFXi5giit-4ydHR99OTxJxl0hko4rxRNubOoy46s01Lb2GB-V96pGYlPxyuB0FKOUkUXwdWYrV7q0djWJ4PDCi0xknj9nO03b-JcMMPxwL4NDCsoFPmeQfPLA61w5IYIsJmx_CwG6GxRANPXU8CxPJww2kNDolrTWYhrfrntdKlJ65GTjr7cgNZc8V_mEvRjQdGs_4xx5A58wFTFxc-G3KRuiQRMaNKFBRzTor_r04_sZHb765ydfs_tD3pxKkt-wndVy7feQeK3sfnSpX2huJQc |
| linkProvider | Wiley-Blackwell |
| linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1Lb9QwELZQkYAL78fyKHPgmlUS23HCDSGqbekWhFqpN8t2bGnVbRLtAyFO_AT-DH-IX8KMk21ZVC6IW5JNRsrmG_vzeOYbxl6pshJ5wC9QSikTkds8MZV3iVdSBJEaW0ad2elRMTkRB6fydGgHRLUwvT7ERcCNPCOO1-TgFJDe9vK-oKoqBinOnBd8jITyOjX4juurT_nllkIaS4aRUoikwHlvO63nSkuUKGmW-F-FvsnFVSx0m9TGWWnvDptv3qdPRjkbr1d27L7-IfX4n174Lrs9sFd408PtHrvmm_vsxnTYn3_AfnxEMn5uYE6pSNAGIGTbuYf1oj2bNThj_vz2naK-0NGNs6ZF_ALVVnymxT_g8Os7OjBLMNAtyDCdoqVhJwlwJvfUcA9MU4OjK4EiUHRl1sAgE7sEii-DjVLUxp_PzOtor90UlgI1Bl6sIKrrPmQne--O306SoTFE0nGleMKNTV1mfJWG2tYeh0jlvaqR21S8MrgixYHKyCL4OrOVK11au5p0cHjhRSYyzx-xnaZt_BMGOAJxL4NDFsoFPmeQf_LA61w5IYIsRmx3CwK660VANJXV8CxPRww2mNDombTdYhrfrpe6VCT2yMnGX29Bdi55rvIRe9zD6dJ-xjlSBz5iKoLi4offVm2IBk1o0IQGHdGgv-iDD_tTOnz6z0--ZDcnx9NDfbh_9P4Zu9WH0SlD-TnbWS3W_gXysJXdjf71C6GOKSI |
| linkToPdf | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV3NbtQwELZQkSou_EO3QJkD16yS2ImT3hBl1Ra2VIhKvVmOf6TVtkm0P6jqiUfgZfpCfRJmnGzLonJB3JJsMlI234w_j2c-M_ZOFqVIPX6BIsuySKRVGunSmcjJTHgR66oIOrPjo3z_RByeZqd9_RP1wnT6EDcJN_KMEK_JwVvr152866cq816JM-U5HyKfvC_yuCCE731Nb1cU4tAxjIxCRDkOe-tVPXdaojpJPce_ynd7XNxFQtc5bRiURo_YdPU6XS3KdLhcVENz-YfS4_9538fsYc9d4X0Htifsnqufss1xvzr_jF0dIxU_13BGhUjQeCBcV2cOlrNmOqlxvLz-8ZNyvtDSjZO6QfQCdVZ8p6k_YPB1LR3oOWhoZ2SYTtFSv44EOI472m4PdG3B0BVP-Se6MqmhF4mdA2WXoQpC1NqdT_RusNes2kqBtgWeLSBo6z5nJ6OP3z7sR_22EFHLpeQR11VsEu3K2NvKOgyQ0jlpkdmUvNQ4H8UwpbPcO5tUpSlMbI0lFRyeO5GIxPEXbKNuarfFAOMPd5k3yEG5wOc0sk_uuU2lEcJn-YDtrCFAtZ0EiKKmGp6k8YDBChIK_ZIWW3TtmuVcFZKkHjnZ-OstyM0znsp0wF52aLq1n3COxIEPmAyYuPnhtzkbokERGhShQQU0qAt1-OVgTIfb__zkW7Z5vDdSnw-OPr1iD7ocOpUnv2Ybi9nSvUEStqh2gnf9AiTJJ9o |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Plasma+level+of+soluble+urokinase-type+plasminogen+activator+receptor+as+a+predictor+of+disease+severity+and+case+fatality+in+patients+with+bacteraemia%3A+a+prospective+cohort+study&rft.jtitle=Journal+of+internal+medicine&rft.au=HUTTUNEN%2C+R&rft.au=SYRJ%C3%84NEN%2C+J&rft.au=VUENTO%2C+R&rft.au=HURME%2C+M&rft.date=2011-07-01&rft.pub=Blackwell&rft.issn=0954-6820&rft.volume=270&rft.issue=1&rft.spage=32&rft.epage=40&rft_id=info:doi/10.1111%2Fj.1365-2796.2011.02363.x&rft.externalDBID=n%2Fa&rft.externalDocID=24243120 |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0954-6820&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0954-6820&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0954-6820&client=summon |